Search

Home > New FDA Approvals > 064 - FDA approves Lynparza (olaparib) in BRCA-mutated metastatic breast cancer; digital health predictions for 2018; upcoming FDA calendar (Lutathera and Trulance)
Podcast: New FDA Approvals
Episode:

064 - FDA approves Lynparza (olaparib) in BRCA-mutated metastatic breast cancer; digital health predictions for 2018; upcoming FDA calendar (Lutathera and Trulance)
Category: Science & Medicine
Duration: 00:11:13
Publish Date: 2018-01-15 07:00:00
Description:

January 15, 2018

Check out the podcast website at newfdaapprovals.com 0:23 FDA approves Lynparza in BRCA-mutated metastatic breast cancer

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm592347.htm 

https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2018/lynparza-approved-by-us-fda-in-germline-brca-mutated-metastatic-breast-cancer-12012018.html 

4:05 Bessemer's Steve Kraus makes his digital health predictions for 2018 https://www.cnbc.com/2018/01/14/bessemers-steve-kraus-makes-his-digital-health-predictions-for-2018.html 

8:49 Upcoming FDA calendar 

Advanced Accelerator Applications S.A.

AAAP

Lutathera (NDA resubmission)

FDA decision on Lutathera for the treatment of patients with gastroenteropancreatic neuroendocrine tumors

Friday 01/26/2018

Synergy Pharmaceuticals, Inc.

SGYP

TRULANCE (sNDA)

FDA decision on TRULANCE for the treatment of adults with irritable bowel syndrome with constipation

Wednesday 01/24/2018 

AI Medicine podcast aimedicinenews.com

Nascent Medical info@nascentmc.com
Total Play: 0